SC
DYN icon

Samlyn Capital’s Dyne Therapeutics DYN Stock Holding History

Samlyn Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.9M Buy
1,922,543
+429,468
+29% +$7.41M 0.59% 52
2025
Q4 		$29.2M Buy
+1,493,075
New +$28.3M 0.47% 55

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Samlyn Capital's DYN Position: Q1 2026 in Review

Samlyn Capital increased its Dyne Therapeutics (DYN) stake by 29% in Q1 2026, buying an estimated $7.41M and bringing the position to 1,922,543 shares worth $34.9M. The position accounts for 0.59% of the portfolio, ranked #52.

Samlyn Capital first reported a position in DYN in Q4 2025 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Samlyn Capital held 1,922,543 shares of Dyne Therapeutics worth $34.9M as of Q1 2026.
  • Samlyn Capital bought 429,468 Dyne Therapeutics shares in Q1 2026, an estimated $7.41M.
  • Dyne Therapeutics made up 0.59% of Samlyn Capital's portfolio in Q1 2026, its #52 holding.
  • Samlyn Capital first reported a position in Dyne Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Samlyn Capital's 13F filing for Q1 2026, filed 15 May 2026.